dihexa clinical trial 2025 D I H E X A is having a moment right now… and I get why. When something gets labeled as “brain repair” or “synapse growth,” it spreads FAST especially in communities dihexa clinical trials status Dihexa

The overall impression from available evidence is that DSIP appears reasonably well-tolerated with a low incidence of serious adverse effects in the populations and contexts studied, but significant gaps in safety knowledge remain, particularly regarding long-term use, use in specific populations (elderly, children, those with comorbidities), and comprehensive toxicology assessment meeting modern pharmaceutical standards

NCT04982575

Methodology notes for researchers Several features of the BPC-157 corpus are worth flagging for anyone weighing the evidence

That approval status is a hard regulatory fact, and it is the single biggest reason a CagriSema-versus-tirzepatide comparison is not a comparison of equals: one product has cleared a full regulatory efficacy-and-safety review, and the other has not yet

It means the better fit depends on what kind of recovery question someone is trying to solve

These precautions preserve peptide integrity